Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

New data from the CHIP-BCIS3 trial reveal that periprocedural myocardial injury only partially explains the nearly doubled cardiovascular death rate seen with Impella CP mechanical support versus standard care in high-risk PCI. Most of the mortality gap remains unexplained, raising deeper questions about what's actually driving the pump's harm signal.
A new analysis from the CHIP-BCIS3 trial, presented at AHA 2026, digs deeper into why patients who received Impella CP mechanical circulatory support during complex PCI fared worse than those on standard care. The original trial — published in the New England Journal of Medicine — found that elective left ventricular unloading with the microaxial flow pump (mAFP) did not reduce major adverse outcomes and was associated with nearly double the rate of cardiovascular death (26.7% vs. 14.5%).
The new mediation analysis confirms that periprocedural myocardial injury is linked to CV mortality, but it only accounts for a minority of the excess deaths in the mAFP group. The vast majority of the mortality signal appears to run through a pathway independent of myocardial injury — leaving clinicians and researchers puzzling over what else may be at play. Procedure duration (about 50 minutes longer with the pump) and more complete revascularization during the index PCI are potential contributors, but neither fully explains the gap.
Key Takeaways:
Why it matters: These findings add to growing concern about routine Impella use in high-risk PCI and are already influencing practice — clinicians report a marked drop in prophylactic Impella use since CHIP-BCIS3. The upcoming PROTECT IV trial, with ~1,200 patients and a more structured care protocol, may help clarify whether device strategy or post-procedural care is the key variable.